BC Tyrosine Kinase Inhibitors Registry and Biorepository, Canada
Objective: Leukemia and Lymphoma are one of the most common cancers found in children and adults. Chemotherapy remains the mainstay treatment option for Leukemia and Lymphoma cancers and the specific use of tyrosine kinase inhibitors have recently revolutionized the treatment for chronic myeloid leukemia and B cell lymphoma malignancies. While this class of chemotherapy agents drastically reduced the rates of mortality and improved survival outcomes, they are thought to be significantly cardiotoxic and predisposes individuals to cardiac co-morbidities later in life. Little remains known about the risk factors associated with tyrosine kinase inhibitors induced cardiotoxicity, and consequently there are no risk-based guidelines that provide treatment protocols for children or adults receiving this therapy. Thus, the overarching goal of this study is to establish a combined clinical registry and genetic biorepository from patients exposed to tyrosine kinase inhibitors to better assess and predict individuals at risk for developing cardiotoxicity.
|Registered Biobank Name||BC Tyrosine Kinase Inhibitors Registry and Biorepository|
|Biobank Leader||Brandon Chalazan|
|Email for biobank firstname.lastname@example.org|
|Principal Investigator||Brandon Chalazan|